Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Disrupting the APC–Asef Interaction Suppresses Cancer Cell Migration

DOI: 10.1158/2159-8290.CD-RW2017-145 Published September 2017
  • Article
  • Info & Metrics
Loading
  • Major finding: Structure-based design yields peptidomimetic APC–ARM pocket inhibitors that block Asef binding.

  • Approach: Targeting the APC–Asef interaction prevents Asef-mediated activation of CDC42, disrupting cell migration.

  • Impact: Inhibition of the APC–Asef interaction may potentially suppress colorectal cancer metastasis.

Asef is a guanine nucleotide exchange factor that specifically activates the small Rho-like GTPases, including CDC42 and RAC1, to promote cell migration. APC binding alleviates the negative regulation of Asef, resulting in aberrant migration of colorectal cancer cells. Thus, the APC–Asef interaction is a potential therapeutic target to disrupt invasive migration in colorectal cancer, but pharmacologic agents that target this interaction are not available. Jiang, Deng, Yang, and colleagues used structure-based drug design to generate peptidomimetic inhibitors that bind to APC to block Asef binding. Asef binds to the ARM domain of APC, and truncated peptides were screened for binding to the APC–Asef interaction hotspot. MAI-005 was the best inhibitor of the APC–Asef interactions, and further optimization including determination of crystal structures and use of cellular assays yielded the more potent inhibitors MAI-150 and MAI-203. These inhibitors bound to the APC–ARM pocket and induced conformation changes in Arg549, Lys586, and Gln542. The inhibitors were conjugated to the transcription trans-activating (TAT) sequence of HIV to improve cell penetration, and, in HEK293T cells, the TAT conjugated compounds MAIT-150 and MAIT-203 directly targeted APC to disrupt the APC–Asef interaction in a dose-dependent manner, with MAIT-203 having the most potent effects. Further, in the colorectal cancer cell lines SW480 and HCT116, the MAIT compounds suppressed cell migration and invasion, but did not affect proliferation or cell morphology. Mechanistically, MAIT-203 prevented CDC42 activation, but not RAC1 activation, indicating that APC promotes cell migration via Asef-mediated activation of CDC42. The design of the first-in-class peptidomimetic inhibitors of the APC–Asef interaction suggests that therapeutic targeting may be feasible, and supports further in vivo testing of these compounds to determine their efficacy in suppressing metastasis in colorectal cancer.

Jiang H, Deng R, Yang X, Shang J, Lu S, Zhao Y, et al. Peptidomimetic inhibitors of APC-Asef interaction block colorectal cancer migration. Nat Chem Biol 2017 Jul 24 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2017 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 7 (9)
September 2017
Volume 7, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Disrupting the APC–Asef Interaction Suppresses Cancer Cell Migration
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Disrupting the APC–Asef Interaction Suppresses Cancer Cell Migration
Cancer Discov September 1 2017 (7) (9) OF8; DOI: 10.1158/2159-8290.CD-RW2017-145

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Disrupting the APC–Asef Interaction Suppresses Cancer Cell Migration
Cancer Discov September 1 2017 (7) (9) OF8; DOI: 10.1158/2159-8290.CD-RW2017-145
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Cell-Intrinsic Programs Partition Nutrients in Tumor Microenvironment
  • Extrachromosomal DNA Can Promote Oncogene Transcription in Trans
  • Transient Rest Reverses Exhaustion of Chimeric Antigen Receptor T Cells
Show more Research Watch

Drug Design

  • De Novo Cytokine Mimics Have Improved Therapeutic Properties
  • A Screen of C2H2 Zinc Fingers Reveals Degrons Targeted by Thalidomide
  • A Paralog-Selective Inhibitor May Allow for Targeting of GSK3α in AML
Show more Drug Design
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement